Try our mobile app
US Leaders — Screener 

Technology
Company / category Price and
change
Year div-d yield FCF Yield LTM Last growth
Revenue/EBITDA
AVG growth
last/hist
EV/LTM EBITDA Express
potential
Next IFRS report Value Creation
Price +/- Revenue EBITDA Last Hist. (exp) (p75)
Apple 291.13 -1.5% 0.4% 1.0% 
15.7% 
17.8%
16.7% 
5.2%
30.4x
Google 358.16 +0.4% 0.2% -0.8% 
21.8% 
31.6%
26.7% 
18.5%
26.6x
Microsoft 390.74 +0.1% 0.9% 1.2% 
16.7% 
23.4%
20.0% 
19.3%
15.6x
Amazon 238.55 -1.2% 0.0% 0.0% 
13.6% 
20.7%
17.2% 
26.1%
16.8x
Broadcom 382.07 -0.9% 0.6% 1.5% 
29.5% 
36.1%
32.8% 
26.2%
64.5x
Facebook 566.98 -0.3% 0.4% 0.0% 
23.8% 
8.4%
16.1% 
32.9%
15.1x
Netflix 80.34 -1.1% 0.0% 2.5% 
17.2% 
11.6%
14.4% 
23.8%
26.8x
Texas Instruments 301.12 +1.4% 1.8% -0.6% 
10.4% 
12.0%
11.2% 
-6.0%
35.4x
Salesforce 165.89 -0.3% 1.0% 0.9% 
8.6% 
11.0%
9.8% 
24.5%
11.9x
Adobe 204.02 -6.8% 0.0% 1.4% 
10.5% 
12.4%
11.5% 
12.7%
9.8x

Payments
Company / category Price and
change
Year div-d yield FCF Yield LTM Last growth
Revenue/EBITDA
AVG growth
last/hist
EV/LTM EBITDA Express
potential
Next IFRS report Value Creation
Price +/- Revenue EBITDA Last Hist. (exp) (p75)
Visa 322.39 +1.0% 0.8% --- 
11.5% 
-4.3%
3.6% 
6.5%
30.3x
Mastercard 489.98 +0.7% 0.6% --- 
17.6% 
21.5%
19.5% 
9.6%
31.8x

Hardware
Company / category Price and
change
Year div-d yield FCF Yield LTM Last growth
Revenue/EBITDA
AVG growth
last/hist
EV/LTM EBITDA Express
potential
Next IFRS report Value Creation
Price +/- Revenue EBITDA Last Hist. (exp) (p75)
Nvidia 205.19 +0.2% 0.0% 0.6% 
73.2% 
83.5%
78.4% 
109.8%
37.6x
QUALCOMM 211.72 +4.3% 1.7% 0.0% 
5.0% 
-5.8%
-0.4% 
2.2%
17.5x

Communications
Company / category Price and
change
Year div-d yield FCF Yield LTM Last growth
Revenue/EBITDA
AVG growth
last/hist
EV/LTM EBITDA Express
potential
Next IFRS report Value Creation
Price +/- Revenue EBITDA Last Hist. (exp) (p75)
Cisco 121.10 -0.6% 1.4% 1.0% 
7.5% 
26.1%
16.8% 
2.8%
32.6x
Verizon 48.11 +2.5% 5.7% 3.3% 
1.5% 
22.5%
12.0% 
4.2%
7.3x
AT&T 23.58 +2.5% 4.7% -0.8% 
3.6% 
2.0%
2.8% 
13.4%
7.2x
Comcast 24.50 +2.2% 5.2% 4.9% 
-2.7% 
-1.9%
-2.3% 
9.4%
5.3x

Entertainment
Company / category Price and
change
Year div-d yield FCF Yield LTM Last growth
Revenue/EBITDA
AVG growth
last/hist
EV/LTM EBITDA Express
potential
Next IFRS report Value Creation
Price +/- Revenue EBITDA Last Hist. (exp) (p75)
Disney 100.04 -0.3% 1.5% 0.1% 
5.2% 
-3.0%
1.1% 
26.1%
12.0x

Consumer Brand
Company / category Price and
change
Year div-d yield FCF Yield LTM Last growth
Revenue/EBITDA
AVG growth
last/hist
EV/LTM EBITDA Express
potential
Next IFRS report Value Creation
Price +/- Revenue EBITDA Last Hist. (exp) (p75)
Procter & Gamble 149.61 +0.9% 2.8% -0.4% 
1.5% 
-4.3%
-1.4% 
5.3%
17.2x
Coca-Cola 82.62 +0.1% 2.5% -0.1% 
2.4% 
-30.4%
-14.0% 
7.0%
26.3x
Philip Morris 184.30 +2.0% 3.1% -0.4% 
9.4% 
14.8%
12.1% 
8.6%
20.0x
PepsiCo 144.27 +0.4% 3.9% -1.7% 
5.6% 
42.6%
24.1% 
6.0%
15.3x
Nike 44.93 -2.2% 3.6% -1.9% 
0.6% 
-27.8%
-13.6% 
-13.3%
86.2x

Food
Company / category Price and
change
Year div-d yield FCF Yield LTM Last growth
Revenue/EBITDA
AVG growth
last/hist
EV/LTM EBITDA Express
potential
Next IFRS report Value Creation
Price +/- Revenue EBITDA Last Hist. (exp) (p75)
McDonalds 284.81 0.0% 2.5% -0.5% 
3.0% 
0.2%
1.6% 
6.7%
18.9x

Retail
Company / category Price and
change
Year div-d yield FCF Yield LTM Last growth
Revenue/EBITDA
AVG growth
last/hist
EV/LTM EBITDA Express
potential
Next IFRS report Value Creation
Price +/- Revenue EBITDA Last Hist. (exp) (p75)
Walmart 121.04 +0.4% 0.8% -0.5% 
5.6% 
10.8%
8.2% 
9.5%
23.7x
Costco Wholesale 982.35 +0.7% 0.5% 1.1% 
15.0% 
12.8%
13.9% 
9.3%
33.6x
Home Depot 328.39 +0.7% 2.8% 1.1% 
-3.8% 
-11.6%
-7.7% 
-0.9%
16.6x

Pharma
Company / category Price and
change
Year div-d yield FCF Yield LTM Last growth
Revenue/EBITDA
AVG growth
last/hist
EV/LTM EBITDA Express
potential
Next IFRS report Value Creation
Price +/- Revenue EBITDA Last Hist. (exp) (p75)
Eli Lilly 1 133.00 -2.4% 0.5% -0.5% 
53.9% 
200.0%
126.9% 
44.0%
42.2x
Johnson & Johnson 240.87 +1.1% 2.2% -1.5% 
6.8% 
78.8%
42.8% 
16.4%
17.0x
AbbVie 227.73 +1.3% 2.9% -0.2% 
10.0% 
0.0%
5.0% 
-1.5%
29.4x
United Health 408.52 +0.7% 2.1% -2.3% 
12.2% 
-44.5%
-16.1% 
6.6%
14.6x
Merck 119.05 -1.4% 2.8% -3.7% 
5.0% 
9.7%
7.3% 
9.6%
12.5x
Thermo Fisher Scientific 469.34 -1.3% 0.4% -22.5% 
4.9% 
5.5%
5.2% 
-3.2%
21.9x
Abbott 88.18 -1.6% 2.7% 0.5% 
4.4% 
16.3%
10.4% 
2.0%
17.7x
Pfizer 26.21 +0.2% 6.6% 7.5% 
-5.9% 
-22.8%
-14.4% 
0.8%
12.3x
Danaher 180.10 -0.4% 0.7% 1.1% 
4.6% 
4.8%
4.7% 
-4.9%
26.6x
Bristol-Myers Squibb 57.13 +0.4% 4.4% 3.7% 
1.3% 
200.0%
100.6% 
10.3%
16.7x

Equipment
Company / category Price and
change
Year div-d yield FCF Yield LTM Last growth
Revenue/EBITDA
AVG growth
last/hist
EV/LTM EBITDA Express
potential
Next IFRS report Value Creation
Price +/- Revenue EBITDA Last Hist. (exp) (p75)
Tesla 406.43 +1.8% 0.0% 0.6% 
11.6% 
-20.1%
-4.3% 
-0.4%
118.8x
Raytheon Technologies 183.53 -0.4% 1.5% 1.9% 
12.1% 
15.5%
13.8% 
14.4%
22.1x

iconductors
Company / category Price and
change
Year div-d yield FCF Yield LTM Last growth
Revenue/EBITDA
AVG growth
last/hist
EV/LTM EBITDA Express
potential
Next IFRS report Value Creation
Price +/- Revenue EBITDA Last Hist. (exp) (p75)
Micron Technology 981.61 -1.4% 0.0% 0.0% 
188.7% 
200.0%
194.3% 
25.3%
74.0x
Market Attractiveness Index

Market Attractiveness Index

calculated as average express-upside for TOP-5 US companies with highest potential

High values of index (>30%), indicate favorable moments for additional cash contributions to the stock market / stock purchases

Current value of the Index is 194.4%

chart technology by TradingView

Invest in a rotating portfolio of top US-based, non-financial companies. Strategy results are shown below. This page contains financial information on the 40 companies we screen for our portfolio. For a detailed overview of our US Leaders strategy and rationale behind it, follow the link

US Leaders
since 2019-08-25

-0.1%

0.5%
day

-1.4%

0.6%
week

+306.4%

161.0%
Since inception

0.0%

SP500
Since inception

Target portfolio structure

Actual Performance
Period Strategy SP&500
 
2019 +9.9% +13.5%
2020 +14.2% +16.2%
2021 +30.6% +27.4%
2022 -17.1% -19.7%
2023 +58.3% +24.2%
2024 +37.6% +23.5%
2025 +29.6% +16.4%
2026 +5.8% +8.4%
 
Annualized +22.9% +15.1%
 
Day -0.1% +0.5%
Week -1.4% +0.6%
Year to date +5.8% 0.0%
Since inception (2019-08-25) +306.4% +161.0%

Portfolio (USD) and S&P500 dynamics (%)
chart technology by TradingView

Reviews


2026-06-07
(review)
Weekly results
for USD strategies

US Leaders: -1.5%

Global Commodities: -8.3%

Trending Ideas: -7.2%

Rising Stars: -3.2%

vs S&P500: -2.6%


2026-05-31
(review)
Weekly results
for USD strategies

US Leaders: -1.2%

Global Commodities: +3.3%

Trending Ideas: +1.5%

Rising Stars: -3.3%

vs S&P500: +1.4%


2026-05-24
(review)
Weekly results
for USD strategies

US Leaders: +1.9%

Global Commodities: +1.3%

Trending Ideas: -2.6%

Rising Stars: -1.7%

vs S&P500: +0.9%


2026-05-18
#reports #GOOG

Google (Web search and mobile software provider) reported for 2026 q1
(2026-02-04, After Market Close):

- Revenue +21.8% YoY (vs +18.0% in previous quarter and historical rate +14.1%)
- EBITDA +31.6% YoY (vs +19.3% in previous quarter and historical rate +23.0%)
- EBITDA margin 42.0% increased compared to 38.9% same period last year
- Net Debt increased by $31.2 bln since the start of the year (0.7% of market cap)
- FCF (LTM) -$36.4 bln (negative), 0.8% of market cap
- EV/EBITDA multiple is 29.6x compared to historical level (75th percentile) of 22x
expected multiple is 32.6x

At the opening of the session the share price went down -6.0%

Growth potential increased by 9.4% to -22.9%

2026-05-17
(review)
Weekly results
for USD strategies

US Leaders: +2.9%

Global Commodities: -3.8%

Trending Ideas: -9.7%

Rising Stars: -2.5%

vs S&P500: +0.1%


2026-05-12
#reports #BMY

Bristol-Myers Squibb ( Pharmaceutical and nutritional products manufacturer ) reported for [2025 q4](https://eninvs.com/press_release.php?source=sec&form_type=10&id=195461)
(2026-02-05, Before Market Open):

- Revenue +1.3% YoY (vs +2.8% in previous quarter and historical rate +1.5%)
- EBITDA +740% YoY (vs +85.8% in previous quarter and historical rate +19.0%)
- EBITDA margin 11.8% increased compared to 1.4% same period last year
- Net Debt increased by $1.6 bln since the start of the year (1.4% of market cap)
- FCF (LTM) +$6.1 bln (positive), 5.2% of market cap
- EV/EBITDA multiple is 16.4x compared to historical level (75th percentile) of 20x
expected multiple is 17.6x

The company showed EPS +$3.46 per share. At the opening of the session the share price went up +2.2%

Growth potential increased by 555.6% to +572.4%

2026-05-10
(review)
Weekly results
for USD strategies

US Leaders: -1.1%

Global Commodities: +0.2%

Trending Ideas: -5.3%

Rising Stars: -1.0%

vs S&P500: +2.3%


2026-05-07
#reports #CVS

CVS health (Prescription drug provider) reported for [2026 q1](https://eninvs.com/press_release.php?ticker=CVS&q=2026 q1&id=943499)
(2026-05-06, Before Market Open):

- Revenue -64.9% YoY (vs +19.5% in previous quarter and historical rate +14.7%)
- EBITDA -35.9% YoY (vs +160.1% in previous quarter and historical rate -16.0%)
- EBITDA margin 3.5% increased compared to 1.9% same period last year
- EV/EBITDA multiple is 19.8x compared to historical level (75th percentile) of 18.8x


2026-05-03
(review)
Weekly results
for USD strategies

US Leaders: +0.2%

Global Commodities: -2.0%

Trending Ideas: +3.4%

Rising Stars: -14.0%

vs S&P500: +0.9%


2026-04-29
#reports #SBUX

Starbucks (Coffee selling company) reported for [2026 q1](https://eninvs.com/press_release.php?ticker=SBUX&q=2026 q1&id=939021)
(2026-04-28, After Market Close):

- Revenue +8.8% YoY (vs +5.5% in previous quarter and historical rate +4.3%)
- EBITDA +17.6% YoY (vs -13.5% in previous quarter and historical rate -7.5%)
- EBITDA margin 13.1% increased compared to 12.1% same period last year
- Net Debt increased by $0.8 bln since the start of the year (0.7% of market cap)
- FCF (LTM) +$1.3 bln (positive), 1.1% of market cap
- EV/EBITDA multiple is 30x compared to historical level (75th percentile) of 21x

At the opening of the session the share price went up +8.2%

2026-04-26
(review)
Weekly results
for USD strategies

US Leaders: -1.7%

Global Commodities: +1.7%

Trending Ideas: +2.4%

Rising Stars: +4.1%

vs S&P500: +2.8%


2026-04-19
(review)
Weekly results
for USD strategies

US Leaders: +0.5%

Global Commodities: -0.3%

Trending Ideas: +2.0%

Rising Stars: +4.2%

vs S&P500: +2.2%


2026-04-12
(review)
Weekly results
for USD strategies

US Leaders: +1.1%

Global Commodities: +1.7%

Trending Ideas: 0.0%

Rising Stars: -2.2%

vs S&P500: +3.6%


2026-04-05
(review)
Weekly results
for USD strategies

US Leaders: +1.9%

Global Commodities: +8.4%

Trending Ideas: +0.7%

Rising Stars: 0.0%

vs S&P500: +3.4%


2026-03-29
(review)
Weekly results
for USD strategies

US Leaders: +1.0%

Global Commodities: +4.9%

Trending Ideas: +1.2%

Rising Stars: +2.0%

vs S&P500: -2.1%


2026-03-28
#reports #AVGO

Broadcom (Digital and analog semiconductors developer ) reported for [2025 q4](https://eninvs.com/press_release.php?source=sec&form_type=10&id=196175)
(2025-12-11, After Market Close):

- Revenue +29.5% YoY (vs +28.2% in previous quarter and historical rate +26.4%)
- EBITDA +36.1% YoY (vs +60.3% in previous quarter and historical rate +26.0%)
- EBITDA margin 45.1% increased compared to 42.9% same period last year
- Net Debt increased by $2.9 bln since the start of the year (0.2% of market cap)
- FCF (LTM) +$27.1 bln (positive), 1.9% of market cap
- EV/EBITDA multiple is 51.1x compared to historical level (75th percentile) of 62x
expected multiple is 42.8x

At the opening of the session the share price went down -6.6%

Growth potential decreased by 7.0% to -37.9%

2026-03-22
(review)
Weekly results
for USD strategies

US Leaders: -2.5%

Global Commodities: -9.0%

Trending Ideas: -1.7%

Rising Stars: -8.5%

vs S&P500: -1.9%


2026-03-15
(review)
Weekly results
for USD strategies

US Leaders: -1.1%

Global Commodities: -1.4%

Trending Ideas: -0.1%

Rising Stars: +2.6%

vs S&P500: -1.6%


2026-03-08
(review)
Weekly results
for USD strategies

US Leaders: -3.3%

Global Commodities: -8.5%

Trending Ideas: -1.4%

Rising Stars: -6.3%

vs S&P500: -2.0%


2026-03-01
(review)
Weekly results
for USD strategies

US Leaders: +1.3%

Global Commodities: +2.8%

Trending Ideas: +0.6%

Rising Stars: +0.6%

vs S&P500: -0.4%


2026-02-28
#reports #ABT

Abbott (Medical products and equipment manufacturer ) reported for [2025 q4](https://eninvs.com/press_release.php?source=sec&form_type=8&id=131825)
(2026-01-22, Before Market Open):

- Revenue +4.4% YoY (vs +6.9% in previous quarter and historical rate +0.9%)
- EBITDA +16.3% YoY (vs +10.9% in previous quarter and historical rate +3.0%)
- EBITDA margin 22.9% increased compared to 20.5% same period last year
- Net Debt increased by $8 bln since the start of the year (3.9% of market cap)
- FCF (LTM) +$8.8 bln (positive), 4.3% of market cap
- EV/EBITDA multiple is 22.9x compared to historical level (75th percentile) of 27.4x
expected multiple is 22.1x

The company showed EPS +$3.74 per share. At the opening of the session the share price went down -13.9%

Growth potential changed insignificantly and equals +24.4%